• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

    17.57 -0.30 (-1.65%)
    Streaming Delayed Price Updated: 1:20 PM EDT, Mar 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 706,910
    Open 17.60
    Bid (Size) 17.55 (100)
    Ask (Size) 17.57 (100)
    Prev. Close 17.87
    Today's Range 17.07 - 17.96
    52wk Range 6.360 - 25.00
    Shares Outstanding 58,310,703
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗
    This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials. 
    Via The Motley Fool
    News headline image
    Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -5.0%
    -5.0%
    1 Month
    +13.8%
    +13.8%
    3 Month
    -15.4%
    -15.4%
    6 Month
    +30.8%
    +30.8%
    1 Year
    +41.8%
    +41.8%

    More News

    Read More
    News headline image
    Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Dyne Therapeutics Inc (NASDAQ:DYN) Reports Narrower-Than-Expected Q4 2025 Loss, Reaffirms Key Clinical Timelines ↗
    Via Chartmill
    News headline image
    Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics to Participate in Upcoming Investor Conferences
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Dyne Therapeutics Stock Was a Big Winner on Wednesday ↗
    Via The Motley Fool
    News headline image
    Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Dyne Therapeutics Stock Tanked on Tuesday ↗
    Via The Motley Fool
    News headline image
    Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More ↗
    Via The Motley Fool
    Topics Artificial Intelligence Bonds Economy
    News headline image
    Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears
    Via MarketMinute
    News headline image
    This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
    Via The Motley Fool
    News headline image
    Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗
    Via The Motley Fool
    News headline image
    Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Dyne Therapeutics Announces Proposed Public Offering of Common Stock
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
    Via MarketMinute

    Frequently Asked Questions

    Is Dyne Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Dyne Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Dyne Therapeutics, Inc. - Common Stock trade on?
    Dyne Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Dyne Therapeutics, Inc. - Common Stock?
    The ticker symbol for Dyne Therapeutics, Inc. - Common Stock is DYN on the Nasdaq Stock Market
    What is the current price of Dyne Therapeutics, Inc. - Common Stock?
    The current price of Dyne Therapeutics, Inc. - Common Stock is 17.57
    When was Dyne Therapeutics, Inc. - Common Stock last traded?
    The last trade of Dyne Therapeutics, Inc. - Common Stock was at 03/24/26 01:20 PM ET
    What is the market capitalization of Dyne Therapeutics, Inc. - Common Stock?
    The market capitalization of Dyne Therapeutics, Inc. - Common Stock is 1.02B
    How many shares of Dyne Therapeutics, Inc. - Common Stock are outstanding?
    Dyne Therapeutics, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.